Benefits
55% reduction in snacking episodes
In the pivotal randomized double-blind placebo-controlled clinical trial, Supresa over 8 weeks resulted in 55% reduction in snacking episodes vs placebo. Among the strongest documented effects on uncontrolled eating behavior in the natural appetite category. Snacking is one of the primary contributors to caloric overconsumption and weight gain — addressing it directly impacts weight management outcomes.
69% decrease in appetite
Same trial documented a 69% decrease in appetite over 8 weeks vs placebo. The appetite reduction effect goes beyond just snacking — it addresses the underlying drive to eat that contributes to caloric overconsumption. Importantly, this works with the body's natural satiety signals rather than artificially suppressing hunger via stimulants.
3× snacking reduction in women snackers (14-day onset)
Subgroup analysis showed women considered 'snackers' experienced snacking reduction as much as 3× over placebo, with effects starting at just 14 days. Snacking primarily affects the female population and is frequently associated with stress — Supresa's mechanism specifically targets this population effectively. Fast 14-day onset supports consumer compliance.
Stress-related overeating mechanism
Supresa induces a feeling of well-being and stress reduction — addressing the source of stress-related overeating and snacking. Unlike stimulant-based appetite suppressants that produce side effects (jitters, anxiety, sleep disturbance), Supresa's serotonergic mechanism reduces stress alongside reducing snacking. The dual mechanism is unique in the appetite control category.
Greater body weight reduction
Supresa intake over 8 weeks resulted in significantly greater body weight reduction vs placebo. The weight loss is a downstream consequence of reduced snacking, reduced appetite, and reduced stress-related overeating — not a direct metabolic effect. Distinguishes Supresa from thermogenic ingredients that increase caloric expenditure (with associated stimulant side effects).
Serotonin pathway modulation
Supresa improves serotonin levels — the neurotransmitter that influences satiety, appetite, mood, compulsiveness, and anxiety. The proposed mechanism is serotonin reuptake inhibition (similar to SSRI medications but much milder). The mechanism explains why Supresa works for stress-related eating: low serotonin contributes to both depression and carbohydrate cravings.
GLP-1 supplement category presence
Supresa is the star ingredient in Kourtney Kardashian's Lemme GLP-1 Daily (developed over 5 years with doctors and scientists). The commercial validation in the high-profile GLP-1 supplement category indicates Supresa's clinical credibility — celebrity supplement brands typically face scrutiny, and selecting a clinically-validated ingredient supports their positioning.
GRAS regulatory status
Supresa is GRAS (Generally Recognized As Safe) under 21 CFR 182.20 as an extract of saffron. The regulatory status supports broad formulation applications — foods and beverages, meal replacements, lollipops, gums, chews, shakes. Saffron has been consumed safely as food for centuries in many cultures, supporting the GRAS classification.
Mechanism of action
Serotonin reuptake inhibition
Supresa's proposed primary mechanism is serotonin reuptake inhibition — the same mechanism class as SSRI antidepressants but much milder in magnitude. Increasing serotonin signaling improves mood, reduces stress, and modulates the brain's satiety signals. Low serotonin contributes to depression alongside carbohydrate cravings — addressing both simultaneously.
Stress-emotional eating circuit modulation
Stress and emotional eating share neural circuitry — chronic stress increases cortisol, which drives cravings for high-calorie palatable foods. Supresa's stress reduction effect (mediated through serotonin) reduces this cortisol-driven craving cycle. Mechanism specifically addresses the psychological component of weight management that metabolic interventions miss.
Satiety signal enhancement
Serotonin is a key satiety neurotransmitter — it signals fullness to the brain and reduces the drive to continue eating. By supporting serotonin pathways, Supresa enhances the body's natural satiety signals rather than artificially suppressing hunger. The approach works with biology rather than against it — supporting sustainable behavior change vs forced restriction.
Saffron bioactive triple-compound contribution
Safranal, crocin, and picrocrocin work synergistically — safranal (volatile compound) provides the primary serotonergic effects, crocin (carotenoid) contributes antioxidant and mood support, and picrocrocin (the precursor to safranal) adds additional bioactivity. The triple-compound standardization ensures reproducible effects vs generic saffron extracts.
Non-stimulant mood and appetite mechanism
Unlike stimulant-based appetite suppressants (caffeine, ephedrine, phentermine) that work via CNS stimulation, Supresa works through serotonergic pathways. The non-stimulant mechanism avoids the side effects of stimulants (jitters, anxiety, sleep disruption, cardiovascular effects) — making Supresa suitable for daily long-term use, evening dosing, and stimulant-sensitive populations.
Clinical trials
Randomized double-blind placebo-controlled clinical trial evaluating Supresa at 176.5 mg/day (88.25 mg twice daily) vs placebo over 8 weeks. Outcomes: hunger, snacking frequency, food cravings, body weight. The pivotal trial supporting the appetite control positioning.
Adult women — primary focus on those identified as 'snackers' (snacking is predominantly female-driven and stress-associated). 8-week intervention.
Supresa over 8 weeks resulted in 55% reduction in snacking episodes vs placebo and 69% decrease in appetite. Significantly greater body weight reduction vs placebo. In the snackers subgroup, snacking reduction reached 3× placebo, with effects starting at just 14 days. Decreased hunger, reduced sugar cravings, and reduced between-meal snacking. Established Supresa as the only saffron with clinical efficacy in weight management.
In vitro and preclinical mechanistic studies on Supresa's mechanism of action via serotonin reuptake inhibition. Established the neurochemical basis for the clinical appetite and stress reduction effects. The mechanistic foundation supports the 'mood-based' appetite control positioning vs metabolic interventions.
Not applicable — in vitro pharmacological assays and preclinical mechanistic studies.
Established serotonin reuptake inhibition as the proposed primary mechanism for Supresa's appetite and stress effects. Saffron's active compounds modulate neurotransmitters involved in mood and stress response — explaining the reduced unplanned snacking episodes alongside improved well-being. Multi-faceted approach combining neurotransmitter modulation, hormone regulation, and anti-inflammatory effects.
Class evidence from broader saffron clinical literature for mood support, anxiety reduction, and cognitive effects. Multiple controlled trials of various saffron extracts for depression, mood, and anxiety published in peer-reviewed journals. Provides class evidence supporting Supresa's mood/stress mechanism beyond the specific appetite control application.
Various — adults across multiple saffron mood/cognitive trials.
Saffron extracts consistently improve mood, reduce anxiety, and support cognitive function across multiple controlled trials. Effects comparable to low-dose SSRI medications in some depression trials. The class evidence supports Supresa's mood-mediated appetite control mechanism — explaining why it works with the body's natural systems rather than artificially suppressing hunger.